Skip to main content
. Author manuscript; available in PMC: 2020 May 2.
Published in final edited form as: Antiviral Res. 2017 Aug 24;146:112–120. doi: 10.1016/j.antiviral.2017.08.014

Table 2.

Neutralizing potency of MAb combinations against tecVLPs in SW-13 cells.

MAb 8A1/11E7 8A1/30F7
tecVLP EC50 (μg/mL) 95% Confidence interval Maximal RLU inhibition (%) EC50 (μg/mL) 95% Confidence interval Maximal RLU inhibition (%)
IbAr10200 0.701 0.545–0.901 99.250 ± 0.107 0.300 0.245–0.368 99.596 ± 0.035
Sudan Al-Fulah 2.137 0.811–5.630 77.166 ± 1.854 0.623 0.300–1.295 92.492 ± 0.783
Turkey 2.521 1.538–4.133 75.7838 ± 1.196 1.485 0.478–4.611 91.150 ± 0.748
Hoti 1.936 0.841–4.458 82.022 ± 0.590 0.518 0.373–0.721 93.128 ± 0.267
Oman 1.431 0.885–2.316 78.350 ± 0.757 0.416 0.322–0.544 90.723 ± 1.155
SPU18/88 0.481 0.357–0.647 98.732 ± 0.923 0.378 0.122–1.170 99.864 ± 0.060
ArD15786 3.502 0.607–20.200 97.857 ± 0.361 0.610 0.153–2.441 99.628 ± 0.028
YL04057 0.22 0.148–0.325 99.269 ± 0.052 0.117 0.075–0.181 99.609 ± 0.071
Afg09 1.501 1.100–2.049 92.285 ± 0.574 0.374 0.288–0.486 93.741 ± 0.388
NIV112143 3.836 0.103–142.9 80.730 ± 0.987 0.911 0.273–3.042 89.616 ± 0.776
Baghdad-12 0.084 0.054–0.130 92.747 ± 4.152 0.146 0.033–0.646 99.973 ± 0.350
MAb 11E7/30F7 8A1/11E7/30F7
tecVLP EC50 (μg/mL) 95% Confidence interval Maximal RLU inhibition (%) EC50 (μg/mL) 95% Confidence interval Maximal RLU inhibition (%)
IbAr10200 0.197 0.124–0.311 99.407 ± 0.154 0.094 0.074–0.119 99.761 ± 0.034
Sudan Al-Fulah 1.346 0.114–15.840 76.376 ± 3.099 0.393 0.294–0.524 91.814 ± 1.071
Turkey 0.526 0.314–0.882 92.349 ± 1.845 0.264 0.198–0.352 96.095 ± 0.906
Hoti 0.951 0.552–1.639 80.918 ± 2.995 0.238 0.181–0.313 94.643 ± 0.460
Oman 0.532 0.292–0.971 86.627 ± 2.426 0.162 0.121–0.216 90.647 ± 1.437
SPU18/88 0.156 0.091–0.269 99.498 ± 0.066 0.119 0.092–0.152 99.437 ± 0.063
ArD15786 1.919 0.053–69.22 96.787 ± 0.398 0.169 0.130–0.219 99.593 ± 0.156
YL04057 0.374 0.203–0.694 99.446 ± 0.103 0.052 0.040–0.066 99.485 ± 0.117
Afg09 0.425 0.017–373 94.520 ± 1.103 0.129 0.103–0.161 96.643 ± 0.358
NIV112143 0.672 0.190–2.372 63.796 ± 6.478 0.400 0.211–0.757 86.476 ± 2.854
Baghdad-12 0.065 0.024–0.176 90.436 ± 2.905 0.045 0.029–0.070 98.243 ± 0.710

Indicated combinations of 8A1, 11E7, and 30F7 were diluted in 2-fold series from 101 to 8× 10−2 αg/mL and incubated with tecVLPs. Percent inhibition was calculated by comparing the signal from tecVLPs incubated with MAbs to signal from mock-treated tecVLPs. EC50 values and 95% confidence intervals are shown, as well as maximal inhibition for each combination of antibodies. Maximal inhibition is shown as standard error of the a mean (n = 4).